A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

3상 완료 NCT03524092

대상 질환	Ulcerative Colitis
임상 단계	3상
스폰서	Eli Lilly and Company
상태	완료
참여자 수	1,328 명
중재(약물)	Mirikizumab SC, Mirikizumab IV, Placebo SC
시작일	2018년 10월 19일
완료일	2021년 11월 3일
결과 공개일	2022년 11월 25일

요약

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

Week 40 · percentage of participants

Maintenance Period: Miri IR - PBO SC	25.1 percentage of participants
Maintenance Period: Miri IR - 200 mg Miri SC	49.9 percentage of participants

p-value	<0.001
Risk Difference (RD)	23.2 (95% CI 15.2–31.2)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский